Genentech has begun offering secret rebates to eye doctors as an apparent inducement to get them to use more of the company’s expensive drug Lucentis rather than a less costly alternative.
Under the program, which started on Oct. 1, medical practices can earn up to tens of thousands of dollars in rebates each quarter if they use a lot of Lucentis and if their usage increases from the previous quarter, according to a confidential document outlining the program that was obtained by The New York Times.
Lucentis, approved in 2006, is mainly used to treat age-related macular degeneration, the leading cause of blindness in the elderly. It costs about $2,000 for each injection, with an injection into the eye needed as often as once a month.
The competition comes from Avastin, another Genentech drug that has the same mode of action. While Avastin is approved only to treat cancer, many retina specialists say it works just as well in the eye as Lucentis. So they are using it off-label because each injection costs only $20 to $50.
Using Avastin instead of Lucentis saves Medicare — and costs Genentech — hundreds of millions of dollars a year.
By the way, if you haven’t read, pharma’s pretty happy with this week’s election results.
Opinions on other issues in news, journals, PR, advertising, marketing
A lot of interesting workshops are happening now at the #NBCCSummit! @garyschwitzer, the publisher of @HealthNewsRevu, is discussing new cancer research news. #BeBold
Comments (6)
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Jay R.
November 6, 2010 at 2:54 pmThere are more than just eye doctors doing this in the medical world. My wife works in a pharmacy and has told me stories about elderly people coming in with high dollar name brand prescriptions, when there are much cheaper generic brands of the drug available.
Thanks for posting this article, it is an eye opener for some of naive people out there.
-Jay R.
Dr. Gayle Eversole
November 9, 2010 at 11:55 amAvastin causes blood clots. Perhaps that may be a reason to avoid the drug.
Actually some studies reported 30+ years ago show that vitamin C in proper form and adequate doses will prevent macular degeneration. Other natural approaches have been studied and shown to be effective.
Hyperbaric O2 and chelation may also be helpful.
It is too bad that mainstream medicine is in such lock step with PhRMA, at the expense of people health.
Laura
November 11, 2010 at 6:36 amIt’s things like this that keep health care costs high and require intervention from the government to right the ship.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like